Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients

Won Young Tak; Soo Young Park; Min Kyu Jung; Seong Woo Jeon; Chang Min Cho; Young Oh Kweon; Sung Kook Kim; Yong Hwan Choi

doi:10.1111/j.1872-034X.2009.00515.x

Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients

Won Young Tak
, Soo Young Park
, Min Kyu Jung
, Seong Woo Jeon
, Chang Min Cho
, Young Oh Kweon
, Sung Kook Kim
, Yong Hwan Choi

Department of Medicine

Kyungpook National University

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

As a pyrimidine analog with potent and sustained antiviral activity against hepatitis B virus, clevudine has been known to have no effect on mitochondrial structure, DNA content, or function. There is little information on the side effects of clevudine, which has not been approved for the treatment of chronic hepatitis B outside of South Korea. We report here two cases of chronic hepatitis B patients who experienced mitochondrial myopathy after clevudine medication. These cases raise concerns about the safety profile of clevudine for the treatment of chronic hepatitis B.

Original language	English
Pages (from-to)	944-947
Number of pages	4
Journal	Hepatology Research
Volume	39
Issue number	9
DOIs	https://doi.org/10.1111/j.1872-034X.2009.00515.x
State	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/j.1872-034X.2009.00515.x

Cite this

@article{387ae85530fd4d58bbdcaec652f14b47,

title = "Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients",

abstract = "As a pyrimidine analog with potent and sustained antiviral activity against hepatitis B virus, clevudine has been known to have no effect on mitochondrial structure, DNA content, or function. There is little information on the side effects of clevudine, which has not been approved for the treatment of chronic hepatitis B outside of South Korea. We report here two cases of chronic hepatitis B patients who experienced mitochondrial myopathy after clevudine medication. These cases raise concerns about the safety profile of clevudine for the treatment of chronic hepatitis B.",

author = "Tak, \{Won Young\} and Park, \{Soo Young\} and Jung, \{Min Kyu\} and Jeon, \{Seong Woo\} and Cho, \{Chang Min\} and Kweon, \{Young Oh\} and Kim, \{Sung Kook\} and Choi, \{Yong Hwan\}",

year = "2009",

doi = "10.1111/j.1872-034X.2009.00515.x",

language = "English",

volume = "39",

pages = "944--947",

journal = "Hepatology Research",

issn = "1386-6346",

publisher = "John Wiley and Sons Inc.",

number = "9",

}

TY - JOUR

T1 - Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients

AU - Tak, Won Young

AU - Park, Soo Young

AU - Jung, Min Kyu

AU - Jeon, Seong Woo

AU - Cho, Chang Min

AU - Kweon, Young Oh

AU - Kim, Sung Kook

AU - Choi, Yong Hwan

PY - 2009

Y1 - 2009

N2 - As a pyrimidine analog with potent and sustained antiviral activity against hepatitis B virus, clevudine has been known to have no effect on mitochondrial structure, DNA content, or function. There is little information on the side effects of clevudine, which has not been approved for the treatment of chronic hepatitis B outside of South Korea. We report here two cases of chronic hepatitis B patients who experienced mitochondrial myopathy after clevudine medication. These cases raise concerns about the safety profile of clevudine for the treatment of chronic hepatitis B.

AB - As a pyrimidine analog with potent and sustained antiviral activity against hepatitis B virus, clevudine has been known to have no effect on mitochondrial structure, DNA content, or function. There is little information on the side effects of clevudine, which has not been approved for the treatment of chronic hepatitis B outside of South Korea. We report here two cases of chronic hepatitis B patients who experienced mitochondrial myopathy after clevudine medication. These cases raise concerns about the safety profile of clevudine for the treatment of chronic hepatitis B.

UR - https://www.scopus.com/pages/publications/69949106858

U2 - 10.1111/j.1872-034X.2009.00515.x

DO - 10.1111/j.1872-034X.2009.00515.x

M3 - Article

AN - SCOPUS:69949106858

SN - 1386-6346

VL - 39

SP - 944

EP - 947

JO - Hepatology Research

JF - Hepatology Research

IS - 9

ER -

Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this